Imaging SV2A in mood disorders

What is the purpose of this trial?

The goal of the study is to determine whether there are alterations in synaptic vesicle glycoprotein 2A (SV2A), a protein expressed ubiquitously in synaptic vesicles, in depression and anxiety and whether ketamine, an N-Methyl-D-aspartate (NMDA) antagonist, normalizes SV2A density at time of its greatest anti-depressant response. We will conduct an examination of SV2A and associated consequences using neuroreceptor imaging and behavioral techniques.

Participation Guidelines

Ages: 18 - 70 years

Gender: Both

Nancy Taylor Foundation for Chronic Diseases, Inc.

Start Date: 03/19/2016

End Date: 03/15/2022

Last Updated: 05/15/2018

Study HIC#: 1511016789

Get Involved

For more information about this study, contact:
Sarah DeBonee
+1 203-737-7066

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 1-877-978-8348.

Trial Image